October 28, 2016 11:50 AM ET


Company Overview of f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.

Company Overview

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H., a biopharmaceutical company, designs, develops, and manufactures novel bispecific monoclonal antibodies for the treatment of serious diseases with a focus on immuno-oncology and inflammatory diseases. It offers Modular Antibody Technology, a proprietary engine that generates bispecific antibodies; Fcab, which offers a fundamentally new binding region within an antibody; mAb2 bispecific monoclonal antibodies; and IP portfolio, including patents, trademarks, and trade secrets. The company was founded in 2006 and is headquartered in Vienna, Austria. It has a research site in Cambridge, the United Kingdom.

Schwarzenbergplatz 7

Vienna,  1030


Founded in 2006


43 72055 4215


43 865 55 56

Key Executives for f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.

Chief Executive Officer
Chief Financial Officer
Chief Business Officer
Vice President of Development
Age: 57
Vice President of Immunology
Compensation as of Fiscal Year 2016.

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Key Developments

F-star Opens New Facility in Cambridge, UK; Appoints Michael Davies as VP Protein Sciences

F-star announced the opening of its new facility in the Eddeva building on the Babraham Research Campus in Cambridge, UK. The new facility will house F-star's expanded team which has grown to just over 60 members of staff over the last year. The company also announced the appointment of Michael Davies as VP Protein Sciences. Mike Davies joins from CPI Biologics where he worked as Head of Analytical Strategy, Biologics. He has over 15 years' experience in the development, manufacture and commercialisation of recombinant protein therapeutics.

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Presents at BioEquity Europe 2016 Conference, May-10-2016

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Presents at BioEquity Europe 2016 Conference, May-10-2016 . Venue: Scandic Hotel, Vester Soegade 6, 1601 Copenhagen, Denmark.

F-Star Biotechnology Limited Partners with AbbVie, Inc

F-star Biotechnology Limited has entered into a collaboration and license agreement with AbbVie Inc. to research and develop bispecific antibodies in immuno-oncology. Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several bispecific monoclonal antibodies (mAb2) drug development candidates from these Fcabs. The AbbVie research activities for this collaboration will be led by AbbVie Biotherapeutics.

Similar Private Companies By Industry

Company Name Region
Activartis Biotech GmbH Europe
APEIRON Biologics AG Europe
Apeptico Forschung und Entwicklung GmbH Europe
Aposcience AG Europe
ARTMA Medical Technologies AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H., please visit www.f-star.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.